Key Highlights

  • 3.55 percent was the October 15, 2026 gain for Eli Lilly (NYSE:LLY), which closed at USD 1,251.61, up USD 42.87, for a market value near USD 1.12 trillion in published market data. The October 16 premarket quote was USD 1,256.62, up 0.40 percent.
  • USD 23.0 billion was second quarter revenue, up 48 percent, as volume rose 60 percent and realized prices fell 13 percent, per the August 5, 2026 company release. Mounjaro sold USD 9.9 billion and Zepbound USD 4.9 billion for Eli Lilly (NYSE:LLY).
  • USD 85.0 billion to USD 87.0 billion is the raised 2026 revenue guidance, up from USD 82 billion to USD 85 billion, while EPS guidance is USD 35.50 to USD 36.50. Third quarter results are due October 29, 2026, so Eli Lilly (NYSE:LLY) faces a high bar.
  • 15.33 percent is Lilly's weight in the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), which closed up 1.86 percent on October 15. Large pharma stocks are reported near record highs as investors rotate toward defensive names, so one stock drives much of the sector move.

What Moved the Stock on October 15

Eli Lilly (NYSE:LLY) closed at USD 1,251.61 inside a 52-week range of USD 783.85 to USD 1,292.65, about 3.2 percent below the high (simple arithmetic on two published numbers). No company announcement explains the jump. Published market data points to a rotation, with large pharma stocks reported near record highs as investors shift from technology toward defensive sectors. Lilly also announced its third quarter reporting date and new Omvoh data in ulcerative colitis and Crohn's disease this week.

How Volume Outruns Price

Second quarter revenue rose 48 percent because volume grew 60 percent while realized prices fell 13 percent. Outside the United States, prices fell 36 percent mainly because Mounjaro joined China's national reimbursement list, which trades a lower price for wider access, and volume there rose 113 percent. Non-GAAP EPS of USD 8.38 included USD 3.03 of acquired development charges, which is why the EPS range was trimmed at the top even as revenue guidance rose.

Analyst Views and Risks

Morgan Stanley set a USD 1,430 target and Cantor Fitzgerald USD 1,440 earlier this month, both above the current quote. Risks are specific: falling price per unit, repeated acquired development charges, and a USD 1.12 trillion value that leaves little room for a soft quarter. Pipeline dates matter too. Lilly has submitted orforglipron, its oral GLP-1, for type 2 diabetes in the United States and plans a retatrutide filing in the first quarter of 2027.

Where Things Stand

It depends. Eli Lilly (NYSE:LLY) can build on the October 15 jump only if third quarter results on October 29, 2026 show volume still outweighing price erosion, because the move had no company-specific trigger and the stock sits about 3.2 percent below its 52-week high. Revenue up 48 percent and guidance raised to USD 85.0 billion to USD 87.0 billion favor continued demand, but a rotation-driven rally can reverse as fast as it formed. Watch realized prices, acquired development charges and any update on the orforglipron and retatrutide filings.